Ken Griffin Diagnostics & Research

Citadel Advisors LLC

$559 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
NTRA Natera, Inc.	$16.3B	$227 Million 0.04% of portfolio	1,430,968	Q4 2024 Reduced 37.14%
TMO Thermo Fisher Scientific Inc.	$211B	$177 Million 0.03% of portfolio	339,940	Q4 2024 Added 104.55%
DHR Danaher Corp	$151B	$135 Million 0.02% of portfolio	586,909	Q4 2024 Reduced 12.58%
A Agilent Technologies, Inc.	$40.5B	$122 Million 0.02% of portfolio	909,903	Q4 2024 Added 300.72%
ICLR Icon PLC	$16.5B	$120 Million 0.02% of portfolio	571,605	Q4 2024 Reduced 1.46%
TWST Twist Bioscience Corp	$2.54B	$65.2 Million 0.01% of portfolio	1,402,257	Q4 2024 Reduced 5.42%
GH Guardant Health, Inc.	$4.85B	$45.3 Million 0.01% of portfolio	1,481,889	Q4 2024 Added 348.51%
IDXX Idexx Laboratories Inc	$37.7B	$32.3 Million 0.01% of portfolio	78,054	Q4 2024 Added 237.9%
CRL Charles River Laboratories International, Inc.	$8.25B	$31.5 Million 0.01% of portfolio	170,626	Q4 2024 Added 1,101.85%
CSTL Castle Biosciences Inc	$688M	$22.2 Million 0.0% of portfolio	834,512	Q4 2024 Added 31.83%
IQV Iqvia Holdings Inc.	$36B	$17.3 Million 0.0% of portfolio	87,937	Q4 2024 Reduced 36.97%
EXAS Exact Sciences Corp	$8.76B	$15.1 Million 0.0% of portfolio	268,644	Q4 2024 Added 2,403.91%
MTD Mettler Toledo International Inc	$29.3B	$11.9 Million 0.0% of portfolio	9,750	Q4 2024 Added 8,844.95%
CDNA Care Dx, Inc.	$1.25B	$10.9 Million 0.0% of portfolio	510,044	Q4 2024 Added 23.89%
MYGN Myriad Genetics Inc	$1.21B	$10.5 Million 0.0% of portfolio	765,241	Q4 2024 Added 1,024.35%
OPK Opko Health, Inc.	$1.29B	$4.72 Million 0.0% of portfolio	3,210,290	Q4 2024 Added 28.33%
FLGT Fulgent Genetics, Inc.	$503M	$4.19 Million 0.0% of portfolio	226,619	Q4 2024 Reduced 25.19%
RDNT Rad Net, Inc.	$3.59B	$4.09 Million 0.0% of portfolio	58,585	Q4 2024 Reduced 56.88%
MEDP Medpace Holdings, Inc.	$10.7B	$2.69 Million 0.0% of portfolio	8,107	Q4 2024 Reduced 50.12%
ILMN Illumina, Inc.	$15.3B	$1.13 Million 0.0% of portfolio	8,444	Q4 2024 Reduced 46.7%
NEO Neogenomics Inc	$1.49B	$912,000 0.0% of portfolio	55,381	Q4 2024 Added 188.05%
WAT Waters Corp	$22.8B	$650,000 0.0% of portfolio	1,753	Q4 2024 Added 79.24%
PSNL Personalis, Inc.	$270M	$572,000 0.0% of portfolio	99,027	Q4 2024 Added 183.02%
PKI Perkinelmer Inc	$15.3B	$493,000 0.0% of portfolio	4,081	Q4 2024 New
NEOG Neogen Corp	$2.17B	$291,000 0.0% of portfolio	24,024	Q4 2024 Reduced 97.86%
NOTV Inotiv, Inc.	$97.3M	$173,000 0.0% of portfolio	41,910	Q4 2024 New
LAB Standard Biotools Inc.	$106M	$142,000 0.0% of portfolio	81,589	Q4 2024 Added 24.24%
ACRS Aclaris Therapeutics, Inc.	$154M	$137,000 0.0% of portfolio	55,347	Q4 2024 Reduced 84.82%
XGN Exagen Inc.	$62.4M	$91,000 0.0% of portfolio	22,349	Q4 2024 Reduced 2.87%
DRIO Dario Health Corp.	$16.3M	$56,000 0.0% of portfolio	71,936	Q4 2024 Added 8.4%
VNRX Volitionrx LTD	$33.2M	$40,000 0.0% of portfolio	68,192	Q4 2024 New
ENZ Enzo Biochem Inc	$25.3M	$32,000 0.0% of portfolio	45,956	Q4 2024 Added 72.81%
BIAF Bio Affinity Technologies, Inc.	$2.29M	$12,000 0.0% of portfolio	13,264	Q4 2024 New
BDSX Biodesix Inc	$38M	$1,000 0.0% of portfolio	1,065	Q4 2024 Reduced 92.4%
SERA Sera Prognostics, Inc.	$126M	$0 0.0% of portfolio	64	Q4 2024 New

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account